Current status and prospects of postoperative adjuvant therapy for hepatocellular carcinoma
10.3760/cma.j.cn115610-20231128-00220
- VernacularTitle:肝细胞癌术后辅助治疗的现状与展望
- Author:
Yongyi ZENG
1
;
Jun FU
;
Kongying LIN
;
Luobin GUO
Author Information
1. 福建医科大学孟超肝胆医院肝胆外科，福州 350001
- Keywords:
Liver neoplasms;
Surgical resection;
Local therapy;
Targeted therapy;
Immunotherapy
- From:
Chinese Journal of Digestive Surgery
2024;23(2):221-227
- CountryChina
- Language:Chinese
-
Abstract:
The high recurrence and metastasis rate of hepatocellular carcinoma (HCC) in patients after hepatectomy significantly impact the prognosis. Exploring effective strategies and indications of postoperative adjuvant therapy for HCC is of great clinical significance in reducing postoperative recurrence rate and improving long-term survival. Traditional local treatment modalities, including transcatheter arterial chemoembolization, hepatic artery infusion chemotherapy, and radiotherapy, continue to play a crucial role in postoperative adjuvant therapy. Recently, the emergence of novel systemic therapy agents, including molecular targeted drugs and immune checkpoint inhibitors, has transformed the landscape of postoperative adjuvant therapy, making the selection of adjuvant therapy more intricate and diverse. The author combines the latest progress in adjuvant therapy to explore the strategies and challenges of postoperative adjuvant therapy for HCC.
